(RTTNews) - Vincerx Pharma, Inc. (VINC), a clinical-stage biopharmaceutical company, and Oqory, Inc. a private biopharmaceutical company, on Wednesday unveiled Phase 1a/1b data for Oqory's anti-TROP2 antibody-drug conjugate or ADC, OQY-3258, showing strong efficacy in treating solid tumors, particularly in various breast cancer subtypes.
The data demonstrated a 76% overall response rate or ORR in previously untreated triple-negative breast cancer or TNBC patients and promising results in HR+/HER2- breast cancer.
OQY-3258 also displayed significant activity in brain metastases, with an intracranial ORR of 41%.
The drug's safety profile was favorable, with manageable hematologic toxicities and no severe skin or lung side effects, differentiating it from other TROP2 ADCs.
Additionally, Vincerx and Oqory announced a strategic merger aimed at advancing OQY-3258 into global Phase 3 trials.
The merger is expected to strengthen both companies' ADC pipelines, with Oqory equity holders set to own approximately 95% of the combined entity.
The companies also revealed interim financing from Oqory's investors to support Vincerx's operations as the merger moves forward.
Currently, VINC is trading at $1.71 up by 3.64%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
